INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE
ORDER A TEST Log In Contact Us
Back TO GENOMIC PROFILING

Tempus Hereditary Cancer Germline Testing (Powered by Ambry Genetics®)

The xG and xG+ assays are validated hereditary cancer tests that detect various types of germline alterations associated with inherited cancer risk.

xG+ (CancerNext-Expanded ®) 77 gene panel associated with both common and rare hereditary cancer types analyzed by DNA sequencing, powered by Ambry Genetics®.

xG (CancerNext®) 36 gene panel associated with common hereditary cancer types analyzed by DNA sequencing, powered by Ambry Genetics®.

+RNAinsight® Optional add-on for xG or xG+ that analyzes RNA to support the classification and detection of DNA variants, powered by Ambry Genetics®.

WHY HEREDITARY CANCER TESTING IS IMPORTANT

Up to 10% of all cancers are associated with hereditary cancer syndromes.1

Hereditary cancer testing can help tailor cancer treatment approaches, clarify risks for additional cancers, and help determine screening and risk reduction options.

Additionally, hereditary cancer testing may help to explain the history of cancer in the family and may assist in the identification of at-risk relatives.

Indications for Hereditary Cancer Testing

CONFIRMATORY GERMLINE TESTING

xG (CancerNext® ) and xG+ (CancerNext-Expanded ® ) provide validated germline testing to confirm potential germline findings identified on somatic reports.

Hereditary cancer germline testing may also be utilized to assess variants suspicious for germline presence detected on tumor only sequencing or liquid biopsy and to test for Lynch syndrome for individuals with MSI-High tumors.

 

VALUE OF GERMLINE RNA ANALYSIS

Decreases the number of splicing variants of unknown significance.2,3

~1 in 25 positive patients may receive negative/inconclusive results without RNA analysis.4

~5% of hereditary cancer cases leverage RNA data in variant interpretation, with patients receiving DNA-only germline testing also benefiting from the technology.2

TESTING LOGISTICS

Turnaround time: ~14-21 days after specimen receipt.

Specimen type(s): peripheral blood (EDTA tube for DNA testing, PAXgene® blood tube for RNA analysis), saliva (Oragene®), or skin punch biopsy (cultured fibroblasts)

Genetic counseling is available (via Genome Medical) to the patient. To request a genetic counseling consultation for your patient, please submit a completed referral form to support@tempus.com.

Download Referral Form
Download Ambry Genetic Counseling Patient Information Sheet

Ordering Flexibility

Tempus offers a variety of options to customize molecular profiling for patients.

  • Order germline and somatic testing in combination to obtain comprehensive results
  • Streamlined ordering process through Tempus Hub, paper requisition, or directly from your EHR
  • +RNAinsight® is available as an add-on to xG (CancerNext®) or xG+ (CancerNext-Expanded®)
  • Familial variant/cascade testing is available for at-risk family members at no additional cost if ordered within 90 days of original xG+ or xG report (out to third degree relatives). Must be submitted by a qualified healthcare professional. Download the Familial Variant Testing Form.
Access Tempus Hub
image description

Documents

view all documents
  • UPCOMING WEBINAR:

    Hereditary xG Test Requisition (Ambry)

    View
  • UPCOMING WEBINAR:

    xG/xG+ Gene List

    View
  • UPCOMING WEBINAR:

    Cultured Fibroblasts Requisition

    View
  • UPCOMING WEBINAR:

    Germline Assay Guide (Ambry)

    View
Financial Assistance

We help provide access to our tests for all patients in financial need

Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission. 

  • Step 1

    Apply for financial assistance online at access.tempus.com.

  • Step 2

    If approved, you will know immediately about the maximum out-of-pocket cost of your testing.

  • Step 3

    Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

    All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

Learn more

  1. Family cancer syndromes. American cancer society. Updated September 14, 2022. Accessed March 29, 2024. https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes.html
  2. Horton C, Hoang L, Zimmermann H, et al. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing. JAMA Oncol. 2024;10(2):212–219. 
  3. Karam R, Conner B, LaDuca H, et al. Assessment of diagnostic outcomes of RNA genetic testing for hereditary cancer. JAMA Netw Open. 2019;2(10). 
  4. Horton C, Hoang L, Grzybowski J, et al.. Expanding the reach of paired DNA and RNA sequencing: results from 450,000 consecutive individuals from a hereditary cancer cohort. Oral presentation presented at: Annual Meeting of the American Society of Human Genetics; 2024 Nov 6-8; Denver, CO.

This is data-driven precision medicine

This is the future of healthcare.